论文部分内容阅读
目的:研究男性乳腺发育、乳腺癌与雌激素水平、雌激素受体(ER)及孕激素受体(PR)之间的关系,探讨男性乳腺发育、乳腺癌患者病因及其临床治疗。方法:用放射免疫检测法测定了35例男性乳腺发育和20例正常献血员血清雌二醇(E2)、睾酮(T);用免疫组织化学SP法测定了35例男性乳腺发育、8例乳腺癌患者乳腺切除标本的ER和PR。结果:男性乳腺发育患者血清E2明显高于正常对照组(P=0·023),而T值两组差异无统计学意义;男性乳腺发育(77·1%、71·4%)、乳腺癌患者(87·5%、75·0%)病理标本ER、PR阳性率均较高。结论:男性乳腺发育、乳腺癌与体内E2水平及乳腺ER、PR相关,可能是机体环境中较高的雌激素及其相关激素一起与局部乳腺ER、PR相互作用,诱发男性乳腺发育,进而可能发展为乳腺癌;ER阻滞剂及降低雌激素水平的芳香化酶抑制剂可用于临床治疗男性乳腺发育和乳腺癌。
Objective: To study the relationship between male breast development, breast cancer and estrogen levels, estrogen receptor (ER) and progesterone receptor (PR), and explore the development of mammary glands in men, the causes of breast cancer, and clinical treatment. METHODS: Serum estradiol (E2) and testosterone (T) levels in 35 male mammary glands and 20 normal blood donors were determined by radioimmunoassay. 35 breast mammary glands and 8 mammary glands were measured by SP immunohistochemistry. ER and PR of breast resection specimens from cancer patients. Results: The serum E2 levels in male breast development patients were significantly higher than those in the normal control group (P=0.023). There was no significant difference in the T value between the two groups; male breast development (77.1%, 71.4%), breast cancer The positive rates of ER and PR in patients with pathological specimens (87.5%, 75.0%) were high. Conclusions: Male breast development, breast cancer and E2 levels in the body, and breast ER, PR, may be the higher estrogen and related hormones in the body’s environment together with the local breast ER, PR interaction, induced male breast development, and may be The development of breast cancer; ER blockers and aromatase inhibitors that reduce estrogen levels can be used for the clinical treatment of male breast development and breast cancer.